Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease
Files
Publication date
2023-06-01
Authors
Shubhakar, Archana
Jansen, Bas C.
Adams, Alex T.
Reiding, Karli
Ventham, Nicholas T.
Kalla, Rahul
Bergemalm, Daniel
Urbanowicz, Paulina A.
Gardner, Richard A.
Wuhrer, Manfred
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
Biomarkers to guide clinical decision making at diagnosis of inflammatory bowel disease [IBD] are urgently needed. We investigated a composite serum N-glycomic biomarker to predict future disease course in a discovery cohort of 244 newly diagnosed IBD patients. In all, 47 individual glycan peaks were analysed using ultra-high performance liquid chromatography, identifying 105 glycoforms from which 24 derived glycan traits were calculated. Multivariable logistic regression was performed to determine associations of derived glycan traits with disease. Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio [HR] 25.9, p = 1.1 × 10-12; 95% confidence interval [CI], 8.52-78.78). Application to an independent replication cohort of 54 IBD patients yielded an HR of 5.1 [p = 1.1 × 10-5; 95% CI, 2.54-10.1]. These data demonstrate the prognostic capacity of serum N-glycan biomarkers and represent a step towards personalised medicine in IBD.
Keywords
biomarker, Crohn's disease, N-Glycans, personalised treatment, prognosis, ulcerative colitis, Taverne, General Medicine
Citation
Shubhakar, A, Jansen, B C, Adams, A T, Reiding, K R, Ventham, N T, Kalla, R, Bergemalm, D, Urbanowicz, P A, Gardner, R A, Wuhrer, M, Halfvarson, J, Satsangi, J, Fernandes, D L & Spencer, D I R 2023, 'Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease', Journal of Crohn's and Colitis, vol. 17, no. 6, pp. 919-932. https://doi.org/10.1093/ecco-jcc/jjad012